Teva Pharmaceuticals has secured FDA approval for the first generic glucagon-like peptide-1 (GLP-1) injectable therapy for weight loss, expanding treatment options amid high demand. The drug, a generic form of liraglutide, mimics natural GLP-1 hormones affecting insulin release and appetite suppression. Unlike the longer-acting semaglutide-based competitors, liraglutide requires daily injections but offers a lower-cost alternative as global GLP-1 shortages persist. This approval could significantly reshape weight management strategies in adults and adolescents above 132 pounds (60 kg).